Related Experiment Videos

Ticarcillin-clavulanic acid pharmacokinetics in preterm neonates with presumed sepsis

A H Burstein1, L E Wyble, P Gal

  • 1Division of Neuropharmacology, Dent Neurologic Institute, Millard Fillmore Hospital, Buffalo, New York 14209.

Insights

Current dosing of ticarcillin-clavulanic acid may lead to low clavulanic acid levels in premature infants. A revised regimen of 50 mg/kg every 6 hours is suggested for better therapeutic outcomes in neonates with sepsis.

Area of Science:

  • Pharmacology
  • Neonatal Medicine
  • Infectious Diseases

Background:

  • Premature low-birth-weight neonates with presumed sepsis require careful antibiotic management.
  • Understanding the pharmacokinetics of antibiotics in this vulnerable population is crucial for effective treatment.

Purpose of the Study:

  • To characterize the pharmacokinetics of ticarcillin and clavulanic acid in premature neonates.
  • To evaluate the current dosing regimen (75 mg/kg every 12 hours) for ticarcillin-clavulanic acid in this population.

Main Methods:

  • Eleven premature neonates (<2,200 g) with presumed sepsis received ticarcillin-clavulanic acid intravenously.
  • Blood samples were collected at specified intervals post-infusion for drug concentration analysis.
  • Drug concentrations were determined using a microbiologic assay.

Main Results:

  • Pharmacokinetic parameters for ticarcillin and clavulanic acid were determined, including clearance and half-life.
  • Analysis revealed a high interpatient variability in pharmacokinetic parameters for both drugs.
  • Current dosing regimens risk subtherapeutic concentrations of clavulanic acid.

Conclusions:

  • The standard 75 mg/kg every 12-hour dosing of ticarcillin-clavulanic acid may be inadequate for premature neonates.
  • A revised dosing strategy of 50 mg/kg every 6 hours is proposed as more rational.
  • Further studies are warranted to confirm optimal dosing for neonatal sepsis treatment.

Related Concept Videos